Genmab A+s

H. Lundbeck A/s

Biontech Se

Hoffmann-la Roche Inc.

Genmab B.v.

Janssen Biotech, Inc.

Roche Palo Alto LLC

Genmab Holding B.v.

Cormorant Pharmaceuticals Ab

Medarex Inc.

Genmag A/s

Paul Parren

Janine Schuurman

Jan Van De Winkel

Edward Norbert Van Den Brink

David Satijn

Aran Frank Labrijn

Rik Rademaker

Tom Vink

Ole Baadsgaard

Yvo Graus

Ibrahim John Malik

Rob N De Jong

Joyce Meesters

Joost J Neijssen

Isil Altintas

Patrick Van Berkel

Martine Van Vugt

Frank Rebers

Bart De Goeij

Pekka Kallunki

Florence Sotty

Karina Fog

Frank Beurskens

Liliana Christina Pereira Montezinho

Esther Breij

Louise Buur Vesterager

Ugur Sahin

Arnout F Gerritsen

Jørgen Petersen

Friederike Gieseke

Ann-Louise Bergstrôm

Erhard Kopetzki

Rene Hoet

Jessica Teeling

Jeffrey B Stavenhagen

Dennis Verzijl

Kay-Gunnar Stubenrauch

Ralf Schumacher

Sandra Verploegen

Marije Overdijk

Debra Hudson

Willem Karel Bleeker

Beat Steiner

Anne Stern

Søren Christensen

Jan G J Van De Winkel

Jacques Himber

Jan Egebjerg

Catharina Emanuele Gerarda Havenith

Ewald T J Van Den Bremer

Miranda Jansen-Molenaar

Dorothee Kling

Michel De Weers

Lars Christian Biilmann Rønn

Denise Leah Williams

Mark Chiu

Riemke Van Dijkhuizen Radersma

Simone De Haij

Thilo Riedl

Stefan Seeber

Ronald P Taylor

Sheri Moores

Margaret A Lindorfer

Simone Oostindie

Patrick Engelberts

Steen Lisby

Hilma Van Der Horst

Martine E D Chamuleau

Tuna Mutis

Joost Neijssen

Maria Elena Fuentes

Pamela Strein

Olaf Mundigl

Klaus-Peter Kuenkele

Elsie M Eugui

Martin Lanzendoerfer

Esther C W Breij

Kristel Kemper

Jorgen Petersen

Kristin Strumane

Bart E C G De Goeij

Sjeng Horbach

Martine Vriesema-van Vugt

Martin John Glennie

Alexander Muik

Michael J Gramer

Stefan Loverix

David P E Satijn

Esther Cornelia Wilhelmina Breij

Haichun Huang

Joerg Thomas Regula

Adelbert Grossmann

Ignace Lasters

Josef Endl

Klaus Edvardsen

Thomas C Nesspor

Adam Zwolak

Jan Olaf Stracke

Sebastian Neumann

Anthony A Armstrong

The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

Agent, uses and methods for treatment

The present invention relates to anti-CD37antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG, for use as a medicament in combination with anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG. The invention also relates to a novel composition of anti-CD37 antibodies having an Fc-Fc 5 interaction enhancing substitution and anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution. In particular, the invention relates to compositions wherein the anti-CD37 antibody binds human CD37 and the anti-CD20 antibody binds human CD20. The invention also relates to compositions where the composition is a pharmaceutical composition and the use of such compositions in treatment of cancer and other diseases.

Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof

The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

Anti-DR5 antibodies and methods of use thereof

Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.

Bispecific EGFR/c-Met antibodies

The present invention relates to a method for controlling the composition of a mixture of two or more different antibodies, such as tow or more different monoclonal antibodies, using chromatography. The mixture is for use as a drug product and the method includes a controlled downstream process for the production of a predetermined ratio of the two or more different antibodies.

Method for producing a controlled mixture of two or more different antibodies

As described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and/or agonistic activity.

Polypeptide variants and uses thereof

Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

Multispecific antibodies against CD40 and CD137

Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.

Antibody variants and uses thereof

The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

Antibodies

Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.

Heterodimeric antibody Fc-containing proteins and methods for production thereof

The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.

Nucleic acid molecules encoding binding agents to CD40 and 4-1BB (CD137)

Antibody variants having decreased or increased ability to mediate CDC due to modifications at the C-terminus of their heavy chains are described. Methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of said antibodies are also described.

Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains

The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

Humanized or chimeric CD3 antibodies

Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed.

Bispecific antibodies against HER2 and CD3

Growing community of inventors

Odijk, Netherlands

Paul Parren